Little Deciphera will hustle positive PhIII survival data on lead cancer drug to the FDA in search of its first OK — shares soar
Deciphera has spent the last 5 years positioning itself as another commercial player-to-be in the hectic oncology arena, steering its way through a $127 million IPO $DCPH in 2017, hiring Pfizer vet Mike Taylor as CEO — and then replacing him with someone with marketing experience last spring.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.